The development of drug tolerance to beta2 adrenergic agents.
D000318:Adrenergic beta-Agonists / Q000627:therapeutic use*; D000328:Adult; D000368:Aged; D001249:Asthma / Q000188:drug therapy / Q000503:physiopathology; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D004361:Drug Tolerance; D004809:Ephedrine / Q000009:adverse effects / Q000627:therapeutic use*; D004983:Ethanolamines / Q000627:therapeutic use*; D005260:Female; D005280:Fenoterol / Q000009:adverse effects / Q000627:therapeutic use*; D005541:Forced Expiratory Volume; D006801:Humans; D008297:Male; D008450:Maximal Midexpiratory Flow Rate; D008875:Middle Aged; D012123:Pulmonary Ventilation
D000318:Adrenergic beta-Agonists; D004983:Ethanolamines; D005280:Fenoterol; D004809:Ephedrine